Inhaler Treatment for COPD and Asthma

Initial Treatment

For patients with COPD and moderate-to-high symptoms, the American Thoracic Society recommends starting with LAMA/LABA dual bronchodilator therapy as initial maintenance treatment, which provides superior lung function improvements with significantly lower pneumonia rates 1, 2
The Global Initiative for Chronic Obstructive Lung Disease suggests that for patients with mild COPD, start with LAMA or LABA monotherapy plus short-acting bronchodilator as needed 1, 2

For patients with COPD who continue having exacerbations on LAMA/LABA, escalate to LAMA/LABA/ICS triple therapy, preferably single-inhaler triple therapy, as recommended by the American College of Chest Physicians 1, 3
The European Respiratory Society recommends considering adding roflumilast for patients with FEV₁ <50% predicted with chronic bronchitis who were hospitalized for exacerbation in the past year 1

For patients with both COPD and concomitant asthma, the American Thoracic Society prefers ICS/LABA combination therapy over LAMA/LABA dual therapy 1, 2

Never prescribe ICS monotherapy in COPD, as it provides no benefit and is explicitly not recommended by the Global Initiative for Chronic Obstructive Lung Disease 1, 2
Avoid long-term oral corticosteroids in stable COPD, as they are not recommended by the American College of Chest Physicians 1
Do not use short-acting bronchodilators alone for maintenance therapy, as long-acting agents should be initiated early, according to the European Respiratory Society 2

Verify proper inhaler technique at each visit, as incorrect use leads to poorly controlled disease, as recommended by the British Thoracic Society 4
For COPD patients on triple therapy with moderate-to-high symptom burden or FEV₁ <80%, continue triple therapy rather than stepping down to dual therapy, as suggested by the American College of Chest Physicians 1